The current status of minimal residual disease assessment in myeloma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The current status of minimal residual disease assessment in myeloma
Authors
Keywords
-
Journal
LEUKEMIA
Volume 28, Issue 2, Pages 239-240
Publisher
Springer Nature
Online
2014-02-05
DOI
10.1038/leu.2013.306
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Minimal residual disease testing in multiple myeloma by flow cytometry: major heterogeneity
- (2013) A. Flanders et al. BLOOD
- Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
- (2013) Andy C. Rawstron et al. JOURNAL OF CLINICAL ONCOLOGY
- Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
- (2013) N Puig et al. LEUKEMIA
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma
- (2012) A. J. Jakubowiak et al. BLOOD
- Could CR mean cure?
- (2011) B. Barlogie et al. BLOOD
- High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
- (2011) B. Paiva et al. BLOOD
- Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
- (2011) F. Gay et al. BLOOD
- Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
- (2010) J.-L. Harousseau et al. BLOOD
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
- (2010) S K Kumar et al. LEUKEMIA
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
- (2009) O. Landgren et al. BLOOD
- F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
- (2009) T. B. Bartel et al. BLOOD
- Treatment of Myeloma: Cure vs Control
- (2009) S. Vincent Rajkumar MAYO CLINIC PROCEEDINGS
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
- (2008) B. Paiva et al. BLOOD
- Evaluation of minimal residual disease in multiple myeloma patients by fluorescent-polymerase chain reaction: the prognostic impact of achieving molecular response
- (2008) Pilar Martínez-Sánchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
- (2008) A. C. Rawstron et al. HAEMATOLOGICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now